Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Menoufia University, Shebin El-Kom, Egypt.
Published: November 2020
AI Article Synopsis
Article Abstract
Background: Alopecia areata is a condition involving hair loss from certain or all areas of the body. It has been considered as an immune-mediated disease, characterized by the infiltration of CD4+ and CD8+ lymphocytes in the hair follicles.
Aim Of The Study: The study aimed to assess whether protein tyrosine phosphatase nonreceptor type 22 gene single nucleotide polymorphism 1858C/T has any relationship with alopecia areata in Egyptian patients and whether it is associated with disease severity or not.
Subjects And Methods: Protein tyrosine phosphatase nonreceptor type 22 (PTPN22) C1858T gene polymorphism was identified using polymerase chain reaction-restriction fragment length polymorphism analysis technique in 60 patients suffering from alopecia areata and 30 age- and sex-matched healthy controls. Disease severity was assessed using SALT score.
Results: CT and TT genotypes were significantly higher in the patients' group (P = .005), OR = 4.38 95% CI [1.48-12.96], with significant statistical predominance of T allele in patients, P = .003, OR = 3.86, 95% CI [1.52-9.77]. There was also a positive significant relationship between protein tyrosine phosphatase nonreceptor type 22 genotype CT and SALT score.
Conclusion: PTPN22 1858T allele is associated with the development and severity of alopecia areata in Egyptians.
Purpose: Alopecia Areata (AA) is a complex autoimmune condition characterized by long-term inflammatory non-scarring patches of hair loss on the face, scalp, and body. Its development involves a combination of genetic, immunological, and environmental factors, making it challenging to understand and treat. This study aims to assess the awareness, beliefs, and psychological impact of patients with Alopecia Areata.
Ocrelizumab is a humanized monoclonal antibody, which acts as an anti-CD20 antibody. It is used as a treatment of both relapsing-remitting multiple sclerosis (RRMS) and Progressive types. The aim of this study is to report the first patient with alopecia universalis after switching from rituximab to ocrelizumab.
Background: Vitiligo is a common disease. Limited studies in Saudi Arabia have explored the detailed clinical characteristics of vitiligo, as outlined in recent consensus reports by vitiligo experts.
Objective: To determine vitiligo prevalence and detailed clinical characteristics in a Saudi cohort.
Objective: Alopecia areata (AA) is an autoimmune skin disease. Observational studies have reported an association between AA and cancer. However, the causal relationship between AA and cancer has not been reported.
